Durvalumab

• Description :

  Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.

• CAS Number :

  1428935-60-7

• Stability :

  ≥ 2 years

• Purity :

  >98% (HPLC)

• Molecular Formula :

  ——

• Notes :

  Research use only, not for human use.

• Receptor :

  PD-1/PD-L1